DK3050574T3 - Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom - Google Patents
Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom Download PDFInfo
- Publication number
- DK3050574T3 DK3050574T3 DK15152886.6T DK15152886T DK3050574T3 DK 3050574 T3 DK3050574 T3 DK 3050574T3 DK 15152886 T DK15152886 T DK 15152886T DK 3050574 T3 DK3050574 T3 DK 3050574T3
- Authority
- DK
- Denmark
- Prior art keywords
- plerixafor
- prevention
- treatment
- pulmonary disease
- chronic obstructive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152886.6A EP3050574B1 (en) | 2015-01-28 | 2015-01-28 | Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3050574T3 true DK3050574T3 (da) | 2020-01-20 |
Family
ID=52434596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15152886.6T DK3050574T3 (da) | 2015-01-28 | 2015-01-28 | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10813911B2 (https=) |
| EP (2) | EP3050574B1 (https=) |
| JP (1) | JP7127988B2 (https=) |
| CN (1) | CN107405405B (https=) |
| AU (1) | AU2016212067B2 (https=) |
| BR (1) | BR112017016347A2 (https=) |
| CA (1) | CA2972319C (https=) |
| DK (1) | DK3050574T3 (https=) |
| EA (1) | EA201791689A1 (https=) |
| ES (1) | ES2764840T3 (https=) |
| IL (1) | IL253688B2 (https=) |
| WO (1) | WO2016120369A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017127810A1 (en) * | 2016-01-22 | 2017-07-27 | Indiana University Research & Technology Corporation | Methods for repairing lung tissue |
| TWI734027B (zh) * | 2017-09-18 | 2021-07-21 | 泰宗生物科技股份有限公司 | 用於治療癌症之組合物 |
| EP4085910A1 (en) * | 2021-05-05 | 2022-11-09 | 4Living Biotech | Use of a compound such as plerixafor for treating a viral pulmonary disease |
| CN119925562B (zh) * | 2023-11-03 | 2025-11-28 | 中国科学院上海药物研究所 | 趋化因子受体2拮抗剂在制备治疗糖尿病并发焦虑症的应用 |
| KR20250133491A (ko) * | 2024-02-28 | 2025-09-08 | 재단법인 오송첨단의료산업진흥재단 | 인간 ccl7에 결합하는 신규한 항체 및 이의 용도 |
| CN118252937B (zh) * | 2024-04-07 | 2024-10-22 | 中山大学 | Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| CA2171761C (en) | 1993-09-14 | 2011-11-15 | Timothy John Williams | Eotaxin: eosinophil chemotactic cytokine |
| JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6806061B1 (en) | 1995-01-19 | 2004-10-19 | Children's Medical Center Corporation | G protein-coupled receptor gene and methods of use therefor |
| US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| AU1208397A (en) | 1995-12-28 | 1997-07-28 | Takeda Chemical Industries Ltd. | Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists |
| DE69709647T2 (de) | 1996-05-20 | 2002-11-07 | Dupont Pharmaceuticals Research Laboratories, Inc. | Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren |
| EP1003743A4 (en) | 1997-01-21 | 2001-04-11 | Merck & Co Inc | 3,3-DISBSTITUED PIPERIDINE LIKE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
| KR100447553B1 (ko) | 1997-02-26 | 2004-09-08 | 화이자 인코포레이티드 | 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 ｍｉｐ-1 알파의 ｃｃｒ1 수용체로의 결합에 대한 선택적 저해제로서의 용도 |
| US6207155B1 (en) | 1997-05-07 | 2001-03-27 | Schering Corporation | Method of eosinophil depletion with antibody to CCR 3 receptor |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP4312957B2 (ja) | 1998-01-15 | 2009-08-12 | キングス・カレツジ・ロンドン | Ｃｃｒ５あるいはｃｘｃｒ４を開裂するリボザイム核酸 |
| AU760208B2 (en) | 1998-02-27 | 2003-05-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | G protein-coupled receptor antagonists |
| US6180348B1 (en) | 1998-04-20 | 2001-01-30 | Weihua Li | Method of isolating target specific oligonucleotide ligands |
| CA2235420A1 (en) | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| EP1050583A4 (en) | 1998-11-24 | 2005-02-02 | Hisamitsu Pharmaceutical Co | INHIBITORS OF HIV INFECTIONS |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| BR0010655A (pt) | 1999-03-24 | 2002-02-13 | Anormed Inc | Compostos heterocìclicos para ligação ao receptor de quimiocina |
| CA2399080C (en) | 2000-02-03 | 2013-05-21 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| BRPI0108923B8 (pt) | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
| GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
| AU2002251913A1 (en) | 2001-02-02 | 2002-08-19 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
| US20050124569A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
| EP1461300B1 (en) | 2001-11-30 | 2011-07-27 | Biogen Idec MA Inc. | Antibodies against monocyte chemotactic proteins |
| AR041786A1 (es) | 2002-03-15 | 2005-06-01 | Novartis Ag | Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento |
| GB0212357D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| PL375263A1 (en) | 2002-07-02 | 2005-11-28 | F.Hoffmann-La Roche Ag | 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists |
| AU2003294290A1 (en) | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. |
| AU2004215679A1 (en) | 2003-02-27 | 2004-09-10 | F. Hoffmann-La Roche Ag | CCR-3 receptor antagonists |
| US20050069955A1 (en) | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| AR046594A1 (es) | 2003-10-16 | 2005-12-14 | Applied Research Systems | Usos terapeuticos de variantes de quemoquina |
| JP2007523159A (ja) | 2004-02-20 | 2007-08-16 | ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド | Ｒｎａ干渉分子の標的送達 |
| AR049386A1 (es) | 2004-05-26 | 2006-07-26 | Janssen Pharmaceutica Nv | Mercaptoimidazoles como antagonistas del receptor ccr2 |
| US20060069123A1 (en) | 2004-09-28 | 2006-03-30 | Mingde Xia | Substituted dipiperidine CCR2 antagonists |
| AU2006203826A1 (en) | 2005-01-07 | 2006-07-13 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| PE20061444A1 (es) | 2005-05-19 | 2007-01-15 | Centocor Inc | Anticuerpo anti-mcp-1, composiciones, metodos y usos |
| GB0517966D0 (en) | 2005-09-02 | 2005-10-12 | Novartis Ag | Organic compounds |
| HUP0500877A2 (en) | 2005-09-22 | 2007-05-29 | Sanofi Aventis | Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates |
| WO2007147026A2 (en) | 2006-06-15 | 2007-12-21 | Centocor, Inc. | Ccr2 antagonists for chronic organ transplantation rejection |
| WO2008049874A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
| CL2008001467A1 (es) | 2007-05-30 | 2008-12-05 | Lilly Co Eli | Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer. |
| PL2175859T3 (pl) | 2007-07-12 | 2012-09-28 | Chemocentryx Inc | Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia |
| WO2009074807A2 (en) * | 2007-12-12 | 2009-06-18 | Imperial Innovations Limited | Methods |
| HUP0800478A2 (en) | 2008-07-31 | 2010-03-01 | Sanofi Aventis | Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands |
| WO2010069979A1 (en) | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| HUE025547T2 (en) | 2008-12-19 | 2016-02-29 | Boehringer Ingelheim Int | Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| CN102459227B (zh) | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
| US8471004B2 (en) | 2009-10-07 | 2013-06-25 | Hoffman-La Roche Inc. | Bicyclic compounds |
| US8445674B2 (en) | 2009-10-21 | 2013-05-21 | Hoffmann-La Roche Inc | Heterocyclyl compounds |
| JP5356323B2 (ja) * | 2010-07-01 | 2013-12-04 | 富士化学工業株式会社 | 新規な非晶質ボセンタン及びその製造方法 |
| CN103298786B (zh) | 2010-10-11 | 2016-01-20 | 埃克希金医药品有限公司 | 芳基磺酰胺盐ccr3拮抗剂 |
| US8921559B2 (en) | 2010-12-01 | 2014-12-30 | Janssen Pharmaceutica Nv | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 |
| EP2685824A4 (en) | 2011-03-17 | 2014-09-10 | Merck Sharp & Dohme | INDUSTRIAL DERIVATIVES USED AS CCR2 ANTAGONISTS |
| US20140178367A1 (en) | 2011-04-07 | 2014-06-26 | The Brigham And Women's Hospital, Inc. | Methods of Treating Inflammatory Diseases by Targeting the Chemoattractant Cytokine Receptor 2 (CCR2) or Chemokine (C-C motif) Ligand 2 (CCL2) |
| HK1197159A1 (en) * | 2011-05-25 | 2015-01-09 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| WO2013000922A1 (en) | 2011-06-27 | 2013-01-03 | Universite Pierre Et Marie Curie (Paris 6) | Ccr2 antagonist peptides |
| WO2013052844A1 (en) * | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| AU2011379300A1 (en) * | 2011-10-18 | 2014-06-05 | Biocon Limited | Acid addition salts of Bosentan |
| US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| US20160015786A1 (en) * | 2013-03-01 | 2016-01-21 | Mater Medical Research Institute Limited | Mobilizing agents and uses therefor |
| WO2014143807A2 (en) * | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
-
2015
- 2015-01-28 ES ES15152886T patent/ES2764840T3/es active Active
- 2015-01-28 EP EP15152886.6A patent/EP3050574B1/en active Active
- 2015-01-28 DK DK15152886.6T patent/DK3050574T3/da active
- 2015-01-28 EP EP19197843.6A patent/EP3613435A1/en not_active Withdrawn
-
2016
- 2016-01-28 BR BR112017016347-0A patent/BR112017016347A2/pt not_active Application Discontinuation
- 2016-01-28 US US15/547,099 patent/US10813911B2/en active Active
- 2016-01-28 JP JP2017540788A patent/JP7127988B2/ja active Active
- 2016-01-28 EA EA201791689A patent/EA201791689A1/ru unknown
- 2016-01-28 CN CN201680008472.9A patent/CN107405405B/zh active Active
- 2016-01-28 CA CA2972319A patent/CA2972319C/en active Active
- 2016-01-28 WO PCT/EP2016/051771 patent/WO2016120369A1/en not_active Ceased
- 2016-01-28 AU AU2016212067A patent/AU2016212067B2/en active Active
-
2017
- 2017-07-27 IL IL253688A patent/IL253688B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL253688A (en) | 2017-09-28 |
| BR112017016347A2 (pt) | 2018-03-27 |
| ES2764840T3 (es) | 2020-06-04 |
| WO2016120369A1 (en) | 2016-08-04 |
| EP3613435A1 (en) | 2020-02-26 |
| EP3050574A1 (en) | 2016-08-03 |
| US20180271831A1 (en) | 2018-09-27 |
| CA2972319A1 (en) | 2016-08-04 |
| CN107405405A (zh) | 2017-11-28 |
| AU2016212067B2 (en) | 2020-10-08 |
| EP3050574B1 (en) | 2019-10-09 |
| AU2016212067A1 (en) | 2017-09-14 |
| CA2972319C (en) | 2023-08-01 |
| IL253688B2 (en) | 2023-05-01 |
| EA201791689A1 (ru) | 2017-11-30 |
| JP7127988B2 (ja) | 2022-08-30 |
| US10813911B2 (en) | 2020-10-27 |
| IL253688B1 (en) | 2023-01-01 |
| JP2018505187A (ja) | 2018-02-22 |
| CN107405405B (zh) | 2021-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| DK3684423T5 (da) | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf | |
| DK3445773T3 (da) | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf | |
| DK3285803T3 (da) | Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine | |
| DK3600281T3 (da) | Kombinationsbehandling til behandling eller forebyggelse af tumorer | |
| DK3472183T3 (da) | Variant adeno-associerede virus og fremgangsmåder til anvendelse | |
| LT3496739T (lt) | Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti | |
| DK3227675T3 (da) | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom | |
| DK3713554T3 (da) | Doseringsanvisninger for vidofludimus til behandling af kroniske inflammatoriske og/eller autoimmunsygdomme | |
| DK3693158T3 (da) | Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer | |
| IL247111A0 (en) | Preventive or therapeutic agent for kidney disease | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3395359T3 (da) | Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose | |
| DK3203997T3 (da) | Valproinsyre til behandling eller forebyggelse af patologiske tilstande forbundet med overskydende fibrinaflejring og/eller trombedannelse | |
| DK3432899T3 (da) | Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis | |
| DK3362449T3 (da) | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose | |
| DK3217963T3 (da) | Fremgangsmåder til behandling af individer med prader-willis syndrom eller smith-magenis syndrom | |
| DK3157531T3 (da) | Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil | |
| DK3050574T3 (da) | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom | |
| EP3324894A4 (en) | LATERAL AND MEDIAL SWITCHING KNEE PROSTHESIS | |
| DK3261642T3 (da) | Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3153511T3 (da) | 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme | |
| DK3532064T3 (da) | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser | |
| HUE064422T2 (hu) | Ciklosporin készítmények pulmonáris krónikus graft kilökõdés megelõzésében vagy kezelésében történõ alkalmazásra |